Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Lung Neoplasms 19Ovarian Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Fallopian Tube Neoplasms 13Colorectal Neoplasms 11Pancreatic Neoplasms 9Carcinoma, Hepatocellular 8Melanoma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large B-Cell, Diffuse 5Prostatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Sezary Syndrome 3Sarcoma 3Rectal Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Glioblastoma 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3

Interventions

Cyclophosphamide 57fludarabine phosphate 48Tacrolimus 39Peripheral Blood Stem Cell Transplantation 37Busulfan 36Mycophenolic Acid 34Whole-Body Irradiation 31Antilymphocyte Serum 28Methotrexate 26Cyclosporine 25fludarabine 23Melphalan 18Filgrastim 15Radiotherapy 14thymoglobulin 12ruxolitinib 12Methylprednisolone 12Cord Blood Stem Cell Transplantation 12Stem Cell Transplantation 11Sirolimus 11Psychiatric Rehabilitation 9Flow Cytometry 9Etoposide 9Specimen Handling 7Granulocyte Colony-Stimulating Factor 7merphos 6Therapeutics 6Decitabine 6Cyclosporins 6Azacitidine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Primary Myelofibrosis × Disulfides × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02871323 2019-08-20

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase 1 Withdrawn
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡